Showing results (121-130 of 139) with videos related to
Sort By:
Pageof 14
Leukemia|October 1, 1993
Mitoxantrone and cytosine arabinoside as treatment for acute myelogenous leukemia (AML) at first recurrenceP K MacCallum, C L Davis, A Z Rohatiner, et al.The Hematology Journal : the Official Journal of the European Haematology Association|January 11, 2003
Comparative genomic hybridization and multiplex-fluorescence in situ hybridization: an appraisal in elderly patients with acute myelogenous leukemiaChristopher D Dalley, Michael J Neat, Nicola J Foot, et al.Annals of Hematology|July 1, 1995
Mitoxantrone and cytosine arabinoside as treatment for acute myeloblastic leukemia in older patientsP K MacCallum, A Z Rohatiner, C L Davis, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 2000
Therapy-related myelodysplasia and secondary acute myelogenous leukemia after high-dose therapy with autologous hematopoietic progenitor-cell support for lymphoid malignanciesI N Micallef, D M Lillington, J Apostolidis, et al.British Medical Journal (Clinical Research Ed.)|April 24, 1982
Short-term treatment for acute myelogenous leukaemiaR Bell, A Z Rohatiner, M L Slevin, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 2, 2001
Detection of chromosome abnormalities pre-high-dose treatment in patients developing therapy-related myelodysplasia and secondary acute myelogenous leukemia after treatment for non-Hodgkin's lymphomaD M Lillington, I N Micallef, E Carpenter, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 14, 2003
Durable remissions of myelodysplastic syndrome and acute myeloid leukemia after reduced-intensity allograftingD C Taussig, A J Davies, J D Cavenagh, et al.Lancet (London, England)|May 21, 1999
Brain structure and neurocognitive and behavioural function in adolescents who were born very pretermA L Stewart, L Rifkin, P N Amess, et al.Hematological Oncology|March 1, 1992
Etoposide in combination with intermediate dose cytosine arabinoside (ID ARA C) given with the intention of further myeloablative therapy for the treatment of refractory or recurrent hematological malignancyJ S Whelan, C L Davis, A Z Rohatiner, et al.British Journal of Haematology|November 1, 1986
Treatment of acute lymphoblastic leukaemia in adultsM J Barnett, M F Greaves, J A Amess, et al.Pageof 14